Mesenchymal stromal cell activation by breast cancer secretomes in bioengineered 3D microenvironments

Ulrich Blache, Edward R. Horton, Tian Xia, Erwin M. Schoof, Lene H. Blicher, Angelina Schönenberger, Jess G. Snedeker, Ivan Martin, Janine T. Erler*, Martin Ehrbar

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

29 Downloads (Pure)

Abstract

Mesenchymal stromal cells (MSCs) are key contributors of the tumour microenvironment and are known to promote cancer progression through reciprocal communication with cancer cells, but how they become activated is not fully understood. Here, we investigate how breast cancer cells from different stages of the metastatic cascade convert MSCs into tumour-associated MSCs (TA-MSCs) using unbiased, global approaches. Using mass spectrometry, we compared the secretomes of MCF-7 cells, invasive MDA-MB-231 cells, and sublines isolated from bone, lung, and brain metastases and identified ECM and exosome components associated with invasion and organ-specific metastasis. Next, we used synthetic hydrogels to investigate how these different secretomes activate MSCs in bioengineered 3D microenvironments. Using kinase activity profiling and RNA sequencing, we found that only MDA-MB-231 breast cancer secretomes convert MSCs into TA-MSCs, resulting in an immunomodulatory phenotype that was particularly prominent in response to bone-tropic cancer cells. We have investigated paracrine signalling from breast cancer cells to TA-MSCs in 3D, which may highlight new potential targets for anticancer therapy approaches aimed at targeting tumour stroma.

Original languageEnglish
Article numbere201900304
JournalLife Science Alliance
Volume2
Issue number3
Number of pages15
ISSN2575-1077
DOIs
Publication statusPublished - 2019

Cite this

Blache, Ulrich ; Horton, Edward R. ; Xia, Tian ; Schoof, Erwin M. ; Blicher, Lene H. ; Schönenberger, Angelina ; Snedeker, Jess G. ; Martin, Ivan ; Erler, Janine T. ; Ehrbar, Martin. / Mesenchymal stromal cell activation by breast cancer secretomes in bioengineered 3D microenvironments. In: Life Science Alliance. 2019 ; Vol. 2, No. 3.
@article{c5a98d46900f4b79b83238d9914a043c,
title = "Mesenchymal stromal cell activation by breast cancer secretomes in bioengineered 3D microenvironments",
abstract = "Mesenchymal stromal cells (MSCs) are key contributors of the tumour microenvironment and are known to promote cancer progression through reciprocal communication with cancer cells, but how they become activated is not fully understood. Here, we investigate how breast cancer cells from different stages of the metastatic cascade convert MSCs into tumour-associated MSCs (TA-MSCs) using unbiased, global approaches. Using mass spectrometry, we compared the secretomes of MCF-7 cells, invasive MDA-MB-231 cells, and sublines isolated from bone, lung, and brain metastases and identified ECM and exosome components associated with invasion and organ-specific metastasis. Next, we used synthetic hydrogels to investigate how these different secretomes activate MSCs in bioengineered 3D microenvironments. Using kinase activity profiling and RNA sequencing, we found that only MDA-MB-231 breast cancer secretomes convert MSCs into TA-MSCs, resulting in an immunomodulatory phenotype that was particularly prominent in response to bone-tropic cancer cells. We have investigated paracrine signalling from breast cancer cells to TA-MSCs in 3D, which may highlight new potential targets for anticancer therapy approaches aimed at targeting tumour stroma.",
author = "Ulrich Blache and Horton, {Edward R.} and Tian Xia and Schoof, {Erwin M.} and Blicher, {Lene H.} and Angelina Sch{\"o}nenberger and Snedeker, {Jess G.} and Ivan Martin and Erler, {Janine T.} and Martin Ehrbar",
year = "2019",
doi = "10.26508/lsa.201900304",
language = "English",
volume = "2",
journal = "Life Science Alliance",
issn = "2575-1077",
publisher = "Life Science Alliance",
number = "3",

}

Blache, U, Horton, ER, Xia, T, Schoof, EM, Blicher, LH, Schönenberger, A, Snedeker, JG, Martin, I, Erler, JT & Ehrbar, M 2019, 'Mesenchymal stromal cell activation by breast cancer secretomes in bioengineered 3D microenvironments', Life Science Alliance, vol. 2, no. 3, e201900304. https://doi.org/10.26508/lsa.201900304

Mesenchymal stromal cell activation by breast cancer secretomes in bioengineered 3D microenvironments. / Blache, Ulrich; Horton, Edward R.; Xia, Tian; Schoof, Erwin M.; Blicher, Lene H.; Schönenberger, Angelina; Snedeker, Jess G.; Martin, Ivan; Erler, Janine T.; Ehrbar, Martin.

In: Life Science Alliance, Vol. 2, No. 3, e201900304, 2019.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Mesenchymal stromal cell activation by breast cancer secretomes in bioengineered 3D microenvironments

AU - Blache, Ulrich

AU - Horton, Edward R.

AU - Xia, Tian

AU - Schoof, Erwin M.

AU - Blicher, Lene H.

AU - Schönenberger, Angelina

AU - Snedeker, Jess G.

AU - Martin, Ivan

AU - Erler, Janine T.

AU - Ehrbar, Martin

PY - 2019

Y1 - 2019

N2 - Mesenchymal stromal cells (MSCs) are key contributors of the tumour microenvironment and are known to promote cancer progression through reciprocal communication with cancer cells, but how they become activated is not fully understood. Here, we investigate how breast cancer cells from different stages of the metastatic cascade convert MSCs into tumour-associated MSCs (TA-MSCs) using unbiased, global approaches. Using mass spectrometry, we compared the secretomes of MCF-7 cells, invasive MDA-MB-231 cells, and sublines isolated from bone, lung, and brain metastases and identified ECM and exosome components associated with invasion and organ-specific metastasis. Next, we used synthetic hydrogels to investigate how these different secretomes activate MSCs in bioengineered 3D microenvironments. Using kinase activity profiling and RNA sequencing, we found that only MDA-MB-231 breast cancer secretomes convert MSCs into TA-MSCs, resulting in an immunomodulatory phenotype that was particularly prominent in response to bone-tropic cancer cells. We have investigated paracrine signalling from breast cancer cells to TA-MSCs in 3D, which may highlight new potential targets for anticancer therapy approaches aimed at targeting tumour stroma.

AB - Mesenchymal stromal cells (MSCs) are key contributors of the tumour microenvironment and are known to promote cancer progression through reciprocal communication with cancer cells, but how they become activated is not fully understood. Here, we investigate how breast cancer cells from different stages of the metastatic cascade convert MSCs into tumour-associated MSCs (TA-MSCs) using unbiased, global approaches. Using mass spectrometry, we compared the secretomes of MCF-7 cells, invasive MDA-MB-231 cells, and sublines isolated from bone, lung, and brain metastases and identified ECM and exosome components associated with invasion and organ-specific metastasis. Next, we used synthetic hydrogels to investigate how these different secretomes activate MSCs in bioengineered 3D microenvironments. Using kinase activity profiling and RNA sequencing, we found that only MDA-MB-231 breast cancer secretomes convert MSCs into TA-MSCs, resulting in an immunomodulatory phenotype that was particularly prominent in response to bone-tropic cancer cells. We have investigated paracrine signalling from breast cancer cells to TA-MSCs in 3D, which may highlight new potential targets for anticancer therapy approaches aimed at targeting tumour stroma.

U2 - 10.26508/lsa.201900304

DO - 10.26508/lsa.201900304

M3 - Journal article

VL - 2

JO - Life Science Alliance

JF - Life Science Alliance

SN - 2575-1077

IS - 3

M1 - e201900304

ER -